Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists

被引:0
作者
Matveev, V. B. [1 ]
Alekseev, B. Ya [2 ,3 ]
Kamolov, B. Sh [1 ,4 ]
Markova, A. S. [1 ]
机构
[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia
[2] Minist Hlth Russia, Natl Med Res Radiol Ctr, 3 2nd Botkinskiy Proezd, Moscow 125284, Russia
[3] Moscow State Univ Food Prod, Med Inst Continuing Educ, 11 Volokolamskoe Shosse, Moscow 125080, Russia
[4] Fund Support Anticanc Org Together Canc, Build 2,2 Starokashirskoe Shosse, Moscow 115522, Russia
来源
ONKOUROLOGIYA | 2021年 / 17卷 / 02期
关键词
prostate cancer; androgen deprivation therapy; hormone therapy; luteinizing hormone-releasing hormone agonists; routine clinical practice; non-interventional study; LEUPROLIDE ACETATE; DELIVERY-SYSTEM; TESTOSTERONE; MEN;
D O I
10.17650/1726-9776-2021-17-2-83-92
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Despite the recent amendments to the guidelines for the treatment of metastatic hormone-sensitive prostate cancer (PCa) implying standard use of luteinizing hormone-releasing hormone (LHRH) agonists in combination with chemotherapy or androgen inhibitors, androgen deprivation therapy (ADT) remains an essential component of treatment for advanced PCa. Testosterone target castration level of 20 ng/dL implies routine measurement of testosterone levels along with prostate-specific antigen (PSA) levels during ADT. It is particularly interesting to evaluate the frequency of achieving castration testosterone level in routine clinical practice. Objective: to assess the frequency of achieving castration testosterone level (20 ng/dL) and maintaining it after 6 months of therapy in patients with hormone-sensitive PCa receiving an LHRH agonist for the first time. Materials and methods. In 2019-2020, Russian Society of Cancer Urologists conducted a non-interventional prospective multicenter study (observational program) aimed to evaluate the efficacy of LHRH agonist (including buserelin, goserelin, leuprorelin or triptorelin) in routine clinical practice in Russia. This study involved 39 cancer urologists and 479 patients aged 18 years and older diagnosed with hormone-sensitive PCa, who started their ADT with LHRH agonists for the first time regardless of the disease stage and previous treatment. Patients received hormone therapy with an LHRH agonist for at least 6 months, visiting their doctor every 3 months (visit 1; visit 2: after 3 months; visit 3: after 6 months). Results. Patients received one of the following drugs: leuprorelin (3.75 mg; 7.5 mg; 22.5 mg; 45 mg; n = 225; 47,0 %), goserelin (3.6 mg; 10.8 mg; n = 132; 27.5 %), buserelin (3.75 mg; n = 67; 14.0 %), and triptorelin (3.75 mg; 11.25 mg; n = 55; 11.5 %). Of 479 patients, 186 (38.8 %) received combination treatment with bicalutamide, 12 (2.5 %) with fluta-mide, 54 (11.3 %) with zoledronic acid, and 11 (2.3 %) with denosumab. Among 146 patients with metastatic PCa, a combination of ADT plus docetaxel was administered to 30 participants (20.6 %), ADT plus abiraterone to 8 participants (5.5 %), and ADT plus enzalutamide to 2 participants (1.4 %). After 6 months of therapy, mean PSA level decreased by 94.2 % (from baseline 118.12 ng/mL to 6.87 ng/mL). Mean testosterone level was 19.0 ng/dL (range: 0.029-100 ng/dL). Among 430 patients, the targeted testosterone level <20 ng/dL was achieved in 257 individuals (59.8 %); the level of 20-50 ng/dL was achieved in 158 individuals (36.7 %); and fifteen patients (3.5 %) had their testosterone level >50 ng/dL. The incidence of adverse events was low; most of them were mild. Conclusion. Our findings suggest that not all patients achieve targeted testosterone level of <20 ng/dL, which corroborates the need for routine monitoring of testosterone levels during therapy to ensure its timely correction. We observed frequent administration of ADT with maximum androgen blockade. In patients with metastatic PCa, the use of standards for combination treatment with docetaxel and androgen inhibitors is limited.
引用
收藏
页码:83 / 92
页数:10
相关论文
共 16 条
  • [1] [Anonymous], 2021, PROST CANC CLIN GUID, P2021
  • [2] Bolla, 2021, EAU ANN C MIL 2021 E
  • [3] A clinical study of 22.5 MG. LA-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer
    Chu, FM
    Jayson, M
    Dineen, MK
    Perez, R
    Harkaway, R
    Tyler, RC
    [J]. JOURNAL OF UROLOGY, 2002, 168 (03) : 1199 - 1203
  • [4] Kaprin D., 2019, MALIGNANT TUMORS RUS
  • [5] Kaprin D., 2019, STATE ONCOLOGICAL CA
  • [6] Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT
    Klotz, Laurence
    O'Callaghan, Chris
    Ding, Keyue
    Toren, Paul
    Dearnaley, David
    Higano, Celestia S.
    Horwitz, Eric
    Malone, Shawn
    Goldenberg, Larry
    Gospodarowicz, Mary
    Crook, Juanita M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) : 1151 - 1156
  • [7] Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer
    Liu, Stephen V.
    Liu, Shanshan
    Pinski, Jacek
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (06) : 769 - 778
  • [8] Matveev VB, 2017, Onkourologiya, V13, P79, DOI 10.17650/1726-9776-2017-13-2-79-86
  • [9] Which Luteinising Hormone-Releasing Hormone Agonist Injection Schedule Do Men with Prostate Cancer Prefer? Results of a European Patient Survey
    Montorsi, Francesco
    Tomlinson, Philippa
    [J]. EUROPEAN UROLOGY, 2015, 67 (01) : 177 - 179
  • [10] Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making
    Oefelein, MG
    Feng, A
    Scolieri, MJ
    Ricchiutti, D
    Resnick, MI
    [J]. UROLOGY, 2000, 56 (06) : 1021 - 1024